The May 20, 2015, article by Baselga et al entitled “Reply to A. Avan et al” (J Clin Oncol 33:1712, 2015) was published with errors in the AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.
Dr Baselga’s COIs were given as:
José Baselga
Honoraria: Roche
They should have read as:
José Baselga
Leadership: Infinity Pharmaceuticals, Aura Biosciences
Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Aura Biomedical, Apogen, Seragon, Aragon, Verastem
Honoraria: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, Seragon
Consulting or Advisory Role: Eli Lilly, Novartis, GRAIL, AstraZeneca
Research Funding: Roche/Genentech
Travel, Accommodations, Expenses: Roche/Genentech
This has been corrected as of January 11, 2019. The author apologizes for the errors.
